Pulmonary Fibrosis in COVID-19

Montreh Tavakkoli*, MD, MA
Department of Medicine, New York Presbyterian-Weill Cornell Medical College, Newyork, USA

Clinical Image

A 42-year-old woman with a history of sickle cell disease and hemolytic anemia was admitted for acute hypoxic respiratory failure due to coronavirus disease 2019 (COVID-19) requiring 16 days of invasive mechanical ventilation. She was paralyzed and proned on the ICU acute respiratory distress syndrome protocol and received plaquenil, doxycycline and tociluzimab for treatment of COVID-19 as well as broad-spectrum antibiotics for empiric treatment of a possible superimposed bacterial pneumonia. She was intubated for 2 weeks, respectively, and was discharged to an acute rehabilitation facility within 6 weeks of initial presentation. Follow-up chest imaging was performed 1 week after discharge. The figures below reveal the chest imaging findings of this patient from a prior admission for hypoxia secondary to acute chest syndrome (e.g. baseline chest CT, Figure 1), findings of acute lung injury during her active COVID-19 infection (Figure 2) and resulting pulmonary fibrosis and traction bronchiectasis following the resolution of her acute COVID-19 infection (Figure 3). While survival among admitted patients is 79%, many develop significant complications such as pulmonary fibrosis and bronchiectasis.

Keywords: COVID-19; Coronavirus; Pandemic; Pulmonary fibrosis

*Corresponding author: Montreh Tavakkoli, MD, MA. Department of Medicine, New York Presbyterian-Weill Cornell Medical College, Newyork, USA. Tel: 212-746-2900; E-mail: mot9028@nyp.org


Copyright: © 2020 Tavakkoli M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.